Summary-level statistics and data are available within the manuscript and its Supporting Information files. However, due to restrictions in the original Informed Consent mandated by United States Veterans Affairs research policy, we are unable to deposit individual-level data included in the manuscript into public repositories. Release of de-identified, individual-level data requires Institutional Board Review approval and will be made available to qualified investigators on a case-by-case basis. All inquiries should be directed to the principal investigator, Marilyn Moy, MD, or to the VA Boston Institutional Review Board at <VHABHSIRB@va.gov>.

Introduction {#sec005}
============

Telomeres, which are comprised of repetitive nucleotide sequences and protein complexes, are located at the distal ends of linear eukaryotic chromosomes and protect against chromosomal degradation and the loss of genetic information. Leukocyte telomere length (LTL) is determined by multiple factors. Initially, LTL may be influenced by intrinsic factors such as genetic sequence variation\[[@pone.0223891.ref001], [@pone.0223891.ref002]\] and extrinsic factors such as perinatal and early life exposures\[[@pone.0223891.ref003], [@pone.0223891.ref004]\]. Throughout an individual's lifetime, aging as well as intrinsic and extrinsic factors progressively shorten LTL--thus, the concept of LTL as an integrative summation of an individual's "biological age" is appealing\[[@pone.0223891.ref005]\].

In chronic obstructive pulmonary disease (COPD), telomeres may contribute to disease susceptibility and development\[[@pone.0223891.ref006], [@pone.0223891.ref007]\] in addition to reflecting lifetime exposures such as cigarette smoke\[[@pone.0223891.ref008], [@pone.0223891.ref009]\]. Longitudinal population-based studies have suggested that individuals with shorter telomeres may be more susceptible to the effects of cigarette smoking\[[@pone.0223891.ref006]\] and multiple cross-sectional studies have confirmed shorter LTL in COPD subjects relative to individuals without airflow limitation\[[@pone.0223891.ref007], [@pone.0223891.ref010]\]. Among subjects with established COPD, decreased LTL is associated with increased airflow limitation, reduced health-related quality of life, accelerated rate of shortening of telomeres, and increased mortality\[[@pone.0223891.ref007], [@pone.0223891.ref010]--[@pone.0223891.ref012]\]. Among a cohort of COPD subjects enriched for a history of acute exacerbations (AEs), shorter LTL was associated with increased risk for future AE\[[@pone.0223891.ref012]\].

Associations between longer LTL and higher exercise capacity, defined as an individual's maximal ability to perform work\[[@pone.0223891.ref013]\], as well as physical activity (PA), defined as any movement that expends energy\[[@pone.0223891.ref013]\], have been previously reported among older adults without COPD\[[@pone.0223891.ref014], [@pone.0223891.ref015]\]. In COPD, exercise capacity and PA are significant predictors of healthcare utilization and mortality\[[@pone.0223891.ref016], [@pone.0223891.ref017]\]. We and others have shown that persons with COPD with higher levels of PA, a modifiable behavior, have better clinical outcomes, such as better functional status, decreased risk of AEs, and decreased risk of dying, independent of pulmonary function\[[@pone.0223891.ref018]--[@pone.0223891.ref021]\]. However, the relationship between telomere length, PA and exercise capacity, and clinical events such as AEs in COPD is currently unknown.

In these analyses, we examine data from 3 well-characterized cohorts of COPD patients to explore the biobehavioral relationships between LTL and PA and exercise capacity, and expand upon previous investigations into the relationship between LTL and AEs\[[@pone.0223891.ref012]\]. We examined the relationship between cross-sectional LTL and (1) directly measured PA, (2) exercise capacity assessed via 6 minute walk test (6MWT), (3) history of AE in the year prior to enrollment, and (4) risk of future AEs.

Materials and methods {#sec006}
=====================

COPD cohorts and assessments {#sec007}
----------------------------

All participants were ≥40 years old with COPD (≥10 pack-years smoking and forced expiratory volume in the first second (FEV~1~) / forced vital capacity (FVC) ratio\<0.70 on spirometry or emphysema on clinical chest CT (for Cohorts 1 and 2)). Exclusion criteria included inability to ambulate, unstable cardiovascular disease, and occurrence of an AE \<4 weeks prior to enrollment. Cohort 1 was comprised of 117 subjects recruited from the pulmonary clinics at the VA Boston Healthcare System in 2012--2016 for participation in a 12-week PA intervention trial \[[@pone.0223891.ref022]\]; data from the baseline visit were used in this analysis. Cohort 2 was comprised of 190 subjects participating in an observational study of PA in COPD subjects and were recruited from VA Boston from 2009--2011\[[@pone.0223891.ref020]\]. Cohort 3 was an observational study of PA in 294 participants enrolled in the COPD Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE) study from 2010--2016 \[[@pone.0223891.ref023]--[@pone.0223891.ref025]\]. Spirometry and 6MWT were performed in all cohorts at enrollment in accordance with American Thoracic Society (ATS) guidelines\[[@pone.0223891.ref026], [@pone.0223891.ref027]\]. Similarities and differences in daily step count assessment and criteria for data inclusion for each cohort are shown in [Table 1](#pone.0223891.t001){ref-type="table"}.

10.1371/journal.pone.0223891.t001

###### Physical activity assessment details by cohort.

![](pone.0223891.t001){#pone.0223891.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------
                                    Cohort 1                               Cohort 2                               Cohort 3
  --------------------------------- -------------------------------------- -------------------------------------- ----------------------------------
  Accelerometer / Pedometer used    Omron HJ-720 ITC                       Omron HJ-720 ITC *and*\                StepWatch Activity Monitor (SAM)
                                                                           StepWatch Activity Monitor (SAM)       

  Valid wear day criteria           ≥100 steps and ≥8 hours of wear time   ≥200 steps and ≥8 hours of wear time   ≥10 hours of wear time

  Minimum number of days assessed   ≥ 5                                    ≥ 5                                    ≥ 3
  --------------------------------------------------------------------------------------------------------------------------------------------------

Data on AEs were collected (1) retrospectively for the year prior to enrollment and (2) prospectively after enrollment in all cohorts. The methods of assessment, definitions of AEs, and type of AE data (count versus binary) are summarized in [Table 2](#pone.0223891.t002){ref-type="table"}.

10.1371/journal.pone.0223891.t002

###### Methods and definitions used in AE assessment by cohort.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               Cohort 1                                                            Cohort 2                                                            Cohort 3
  ------------------------------------------------------------ ------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------
  *History of Exacerbations in the Year Prior to Enrollment*                                                                                                                                           

  Method                                                       Self-reported                                                       Self-reported                                                       Self-reported

  Period queried                                               Year prior to enrollment                                            Year prior to enrollment                                            Year prior to enrollment

  Type of data                                                 Count                                                               Binary (Yes/No)                                                     Count

  Question(s) used to assess AE                                "Number of exacerbations in the past year"                          "Physician diagnosed 'flare' of COPD in the past year"              Number of courses of prednisone use in past year

  *Future Exacerbations After Enrollment*                                                                                                                                                              

  Method                                                       Telephone interview & medical record validation every 3--4 months   Telephone interview & medical record validation every 3--4 months   Telephone interview\
                                                                                                                                                                                                       every 3--4 months

  Period of follow-up (years)                                  1.5 ±0.3                                                            1.2 ±0.3                                                            2.2 ±5.3

  Definition / Severity of AE                                                                                                                                                                          

  **Mild**                                                     Not assessed                                                        Not assessed                                                        Count data available

  **Moderate-to-Severe**                                       Count data available                                                Count data available                                                Count data available
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mild exacerbations were defined as ≥2 consecutive days of increased respiratory symptoms. Moderate-to-severe exacerbations were defined as increased symptoms (above) *plus* new antibiotic or systemic steroid use *or* hospitalization.

Study protocols for Cohorts 1 and 2 were approved by VA Boston (IRB Protocols \#2328 and \#1961, respectively). Cohort 3 was approved by the University of Washington, Seattle (Approval 37332), VA Puget Sound Health Care System (Approval 00240), and the University of Texas Health Science Center at San Antonio/South Texas Veterans Health Care System (Approval HSC20100373H). Written informed consent was obtained from all subjects.

Telomere length analysis {#sec008}
------------------------

Blood for LTL analyses was collected at baseline in all cohorts. Genomic DNA was extracted from buffy coat samples. The relative LTL was assessed using a modified, high-throughput real-time quantitative polymerase chain reaction (PCR) assay\[[@pone.0223891.ref028]\]. All samples were processed and analyzed in a single batch; for specific details regarding LTL data generation, please see the Supplementary Methods ([S1 File](#pone.0223891.s001){ref-type="supplementary-material"}) \[[@pone.0223891.ref029]\].

Statistical analysis {#sec009}
--------------------

Analyses were performed in the three combined cohorts to assess associations between the entire range of LTL and average daily step count, 6MWT distance, and number of AEs; pooled analyses were adjusted for cohort. Because average daily step count was assessed using two different devices (SAM and Omron monitors), we examined the correlation between LTL and PA 1) separately in each cohort and 2) in pooled groups by device type. Generalized linear models (PROC GLM, SAS version 9.4) assessed for associations between LTL and PA and exercise capacity, adjusting for factors (e.g. age, FEV~1~/FVC, sex, and race) associated with LTL on univariate analyses. Depending upon the distribution of AE data in each cohort, Poisson, zero-inflated Poisson, and negative binomial models adjusting for age, FEV~1~/FVC, sex, non-white race and follow up time (in analyses using prospective data), were constructed to examine the associations between LTL and the number of AEs. In zero-inflated models, FEV~1~% predicted was used as a covariate in the zero model. In Cohort 2, logistic regression was used to analyze the occurrence of AE (assessed as yes/no) in the year prior to study entry. (See Supplementary Methods--[S1 File](#pone.0223891.s001){ref-type="supplementary-material"})

Results {#sec010}
=======

Cohort characteristics {#sec011}
----------------------

Participant characteristics by cohort and combined are shown in [Table 3](#pone.0223891.t003){ref-type="table"}. The majority of participants were male (89.5%) and white (89.7%) with extensive lifetime exposure to cigarette smoke. Significant differences in baseline characteristics were observed between the three cohorts. Subjects in Cohort 2 had the highest mean age and cumulative exposure to cigarette smoke (pack-years), while subjects in Cohort 3 had the lowest mean FEV~1~% predicted, 6MWT distance, and LTL. Correlations between baseline PA and 6MWT in each cohorts are shown in Supplementary ([S1 Table](#pone.0223891.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0223891.t003

###### Participant characteristics by cohort.
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                                               Cohort 1        Cohort 2        Cohort 3        Combined Cohort   p-value
  -------------------------------------------- --------------- --------------- --------------- ----------------- ----------
  Age (years) (n = 600)                        68.58 ± 8.37    71.647 ± 8.66   67.62 ± 8.46    69.08 ± 8.68      \< .0001
  Sex (Male)                                   115 (98.29)     187 (98.42)     236 (80.27)     538 (89.52)       \< .0001
  Race (Non-white)                             10 (8.55)       12 (6.32)       40 (13.61)      62 (10.32)        0.03
  BMI (kg/m2)                                  28.98 ± 5.54    29.01 ± 6.37    28.13 ± 6.05    28.58 ± 6.06      0.2161
  Current Smoker (n = 600)                     43 (36.75)      46 (24.34)      80 (27.21)      169 (28.17)       0.06
  Pack Years (n = 588)                         59.17 ± 40.83   66.09 ± 36.95   56.69 ± 29.51   60.18 ± 34.63     0.0145
  FEV~1~ (liters) (n = 594)                    1.86 ± 0.61     1.58 ± 0.61     1.27 ± 0.54     1.48 ± 0.62       \< .0001
  FVC (liters) (n = 594)                       3.29 ± 0.79     3.01 ± 0.79     2.97 ± 0.85     2.97 ± 0.85       \< .0001
  FEV~1~/FVC (n = 594)                         0.56 ± 0.11     0.52 ± 0.12     0.45 ± 0.12     0.49 ± 0.13       \< .0001
  FEV~1~% predicted (n = 593)                  61.98 ± 21.28   55.92 ± 20.99   41.8 ± 15.08    50.29 ± 20.26     \< .0001
  FVC % predicted (n = 593)                    80.66 ± 19.46   77.19 ± 19.06   69.25 ± 16.73   74.03 ± 18.65     \< .0001
  MOS score (n = 599)                          3.61 ± 1.12     3.76 ± 1.06     3.72 ± 1.09     3.71 ± 1.09       0.4831
  MMRC dyspnea score                           1.62 ± 1.14     2.14 ± 1.20     1.91 ± 1.1      1.92 ± 1.15       0.0005
  Heart Attack Ever (n = 600)                  9 (7.69)        50 (26.46)      46 (15.65)      105 (17.50)       \< .0001
  Congestive Heart Failure (CHF)               8 (6.84         23 (12.11)      15 (5.10)       46 (7.65)         0.02
  Diabetes                                     29 (24.79)      51 (26.84)      66 (22.45)      146 (24.29)       0.54
  Depression                                   45 (38.46)      52 (27.37)      79 (26.87)      176 (29.28)       0.05
  Arthritis                                    42 (35.90)      97 (51.05)      101 (34.35)     240 (39.93)       0.0007
  Use of Oxygen during Rest (n = 600)          7 (5.98)        20 (10.58)      52 (17.69)      79 (13.17)        0.003
  6MWT Distance (m)                            386 ± 83        369 ± 105       334 ± 113       355 ± 107         \< .0001
  Mean Baseline Step Count---Omron (n = 292)   3457 ± 2462     2851 ± 2373     \-\--           3084 ± 2421       0.0371
  Mean Baseline Step Count---SAM (n = 459)     \-\--           5726 ± 3156     6043 ± 3345     5917 ± 3271       0.3093
  Exp ddCt (Telomere Length)                   0.54 ± 0.10     0.59 ± 0.10     0.52 ± 0.10     0.54 ± 0.10       \< .0001

Data are shown as mean ± SD or n (%). P-values are for Tukey's test for differences in means by cohort (continuous variables) or Chi-square test (categorical variables). MOS SF-36 = Medical Outcomes Study Short-Form 36 questionnaire. MMRC = modified Medical Research Council. 6MWT = 6-minute walk test. SAM = StepWatch Activity Monitor.

Telomere length and baseline characteristics {#sec012}
--------------------------------------------

Associations between LTL and clinically relevant continuous and categorical variables are shown in Supplementary ([S2 Table](#pone.0223891.s003){ref-type="supplementary-material"}). A significant inverse relationship between shorter LTL and higher chronological age at enrollment was observed in the combined cohort. Longer average LTL was significantly associated with non-white race, self-reported history of depression, and higher FEV~1~/FVC ratio in the combined cohort. Current smoking at enrollment was nominally associated with longer average LTL relative to non-current smokers in the combined cohort; however, cumulative pack-years was not significantly associated with LTL in any of the cohorts.

Telomere length and baseline physical activity {#sec013}
----------------------------------------------

No significant correlations between LTL and average daily step count were identified in the individual cohorts. In combined analyses grouped by PA monitoring device, LTL demonstrated a weak but significant positive correlation with Omron-assessed steps from Cohorts 1 (n = 112) and 2 (n = 180) combined (rho = 0.16, p-value = 0.01). However, this association did not remain significant in multivariate models adjusted for age, sex, non-white race, and FEV~1~/FVC ratio ([S3 Table](#pone.0223891.s004){ref-type="supplementary-material"}). No correlation between LTL and SAM-assessed average daily step count was observed in either Cohort 2 or 3 individually or in a combined cohort. A post-hoc random-effects meta-analysis, conducted using Omron-assessed daily step count in Cohorts 1 and 2 and SAM-assessed daily step count in Cohort 3, did not demonstrate a significant association between LTL and average daily step count ([S4 Table](#pone.0223891.s005){ref-type="supplementary-material"}).

Telomere length and baseline exercise capacity {#sec014}
----------------------------------------------

In the combined cohort, a positive correlation (rho = 0.15, p = 0.0002) between longer LTL and greater 6MWT distance was observed, which remained significant in multivariate models adjusting for age, sex, race, and FEV~1~/FVC ratio ([Table 4](#pone.0223891.t004){ref-type="table"}).

10.1371/journal.pone.0223891.t004

###### Multivariate model of baseline leukocyte telomere length and 6-minute walk test distance (meters) in a combined cohort (Cohorts 1, 2, and 3).
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  Continuous measures    β                    95% CI           p-value
  ---------------------- -------------------- ---------------- ---------
  6MWT Distance (m)      0.00003              0.00, 0.00       0.045
  Age                    -0.0019              -0.003, -0.001   0.0002
  FEV~1~/FVC             0.1167               0.05, 0.18       0.001
  Categorical measures   Least Square Means   95% CI           p-value
  Race                                                         0.002
      White              0.5346               0.52, 0.55       
      Non-white          0.5800               0.55, 0.61       
  Sex                                                          0.847
      Male               0.5560               0.54, 0.57       
      Female             0.5586               0.53, 0.59       

6MWT = 6-minute walk test. Generalized linear models were constructed with leukocyte telomere length as the independent variable and 6MWT as the independent variable, with adjustment for age, FEV~1~/FVC ratio, non-white race, and sex.

Telomere length and acute exacerbations in the year prior to enrollment {#sec015}
-----------------------------------------------------------------------

Since historical AE frequency was assessed differently in the 3 cohorts, separate models were used in each cohort. Shorter LTL at baseline was significantly associated with a greater number of AEs in the year prior to enrollment in Cohort 1 ([Table 5](#pone.0223891.t005){ref-type="table"}). Using a similar model, there was a similar direction of effect with a trend towards significance in Cohort 3 (p = 0.1). A significant association between shorter LTL and greater number of AEs in the year prior to enrollment was observed in a combined analysis of both Cohorts 1 and 3. No significant association was observed between LTL and binary history of AE (yes/no) in the year prior to enrollment in Cohort 2. When we examined dichotomized history of AEs (yes/no) in all 3 cohorts combined, no significant association with LTL was observed.

10.1371/journal.pone.0223891.t005

###### Association between baseline leukocyte telomere length and number of acute exacerbations in the year prior to enrollment.
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                                                                  Coeff   95% CI          p-value
  --------------------------------------------------------------- ------- --------------- ---------
  Cohort 1                                                        -8.31   -15.41, -1.20   0.02
  Cohort 3                                                        -1.58   -3.45, 0.28     0.1
  Combined (Cohorts 1 & 3)[\*](#t005fn002){ref-type="table-fn"}   -1.93   -3.72, -0.13    0.04

Coeff = Regression coefficient. Zero-inflated Poisson models were constructed for each analysis with telomere length as the independent variable and the number of acute exacerbations in the year prior to enrollment as the dependent variable. All analyses included adjustment for age, FEV~1~/FVC ratio, non-white race, and sex; FEV ~1~% predicted was included as a predictor in the zero model. Each row of the table represents the results of a separate model.

\* Model additionally adjusted for cohort as a categorical variable.

Telomere length and future acute exacerbation risk {#sec016}
--------------------------------------------------

The average duration of follow-up for all cohorts combined was 1.8 ±3.8 years with significant differences by cohort ([Table 2](#pone.0223891.t002){ref-type="table"}); duration of follow-up was used as an offset in all models. The distribution of all moderate-to-severe AEs in the combined cohort is shown in Supplementary ([S1 Fig](#pone.0223891.s007){ref-type="supplementary-material"}); based on this distribution, a negative binomial model was constructed with the number of AEs as the dependent variable and LTL as the predictor, with covariate age, FEV1% predicted, and cohort--no significant associations were observed ([S5 Table](#pone.0223891.s006){ref-type="supplementary-material"}). However, given the evidence of significant heterogeneity between cohorts, we examined for associations within each cohort separately. The distribution of moderate-to-severe AEs in each individual cohort is shown in Supplementary ([S2 Fig](#pone.0223891.s008){ref-type="supplementary-material"}). Separate negative binomial regressions in Cohorts 1, 2, and 3 did not demonstrate any associations between moderate-to-severe AEs and LTL. Because additional data on *mild* AEs was available in Cohort 3, we examined the distribution of all prospective AEs (mild-moderate-severe; [Fig 1](#pone.0223891.g001){ref-type="fig"}) and performed a subgroup analysis using a multivariate Poisson regression and observed a significant association between LTL and total AEs ([Table 6](#pone.0223891.t006){ref-type="table"}).

![Distribution of all prospective acute exacerbations (mild-moderate-severe) in Cohort 3.](pone.0223891.g001){#pone.0223891.g001}

10.1371/journal.pone.0223891.t006

###### Multivariate Poisson regression of baseline leukocyte telomere length and number of prospective acute exacerbations (mild-moderate-severe inclusive) after study enrollment in Cohort 3.
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                                            Coeff   95% CI          p-value
  ----------------------------------------- ------- --------------- ----------
  Continuous variables                                              
  Leukocyte telomere length                 -1.34   -2.07, -0.61    0.0003
  FEV~1~% predicted (post bronchodilator)   -0.02   -0.02, -0.01    \<0.001
  Age                                       -0.01   -0.02, -0.003   0.0098
  Categorical variables                                             
  Race (reference = white)                  -0.19   -0.44, 0.07     0.1455
  Sex (reference = male)                    0.52    0.36, 0.68      \<0.0001
  Current smoking (reference = no)          0.14    -0.02, 0.31     0.0923

Poisson regression was constructed using leukocyte telomere length as the independent variable and number of all acute exacerbations (mild-moderate-severe) as the dependent variable, with covariates listed above. Follow-up time in years was included as the offset. Coeff = regression coefficient

Discussion {#sec017}
==========

Accelerated cellular senescence has been postulated to contribute to the pathogenesis of COPD\[[@pone.0223891.ref030]--[@pone.0223891.ref032]\]. Reduced LTL, often considered a biomarker for biological aging, has been associated with exposure to oxidative and inflammatory damage as well as poor health outcomes and increased mortality among COPD patients\[[@pone.0223891.ref012], [@pone.0223891.ref033]--[@pone.0223891.ref035]\]. Healthy lifestyle factors, such as engagement in PA, are associated with reduced levels of inflammatory biomarkers and risk for AEs in COPD patients\[[@pone.0223891.ref018], [@pone.0223891.ref020], [@pone.0223891.ref021], [@pone.0223891.ref036]\]. Our study demonstrates that LTL is associated with exercise capacity, and both past and future AEs among subgroups of participants with COPD from 3 independent studies based in the United States.

A key finding was a significant association between baseline LTL and exercise capacity, assessed as the 6MWT distance, after adjusting for age and severity of airflow obstruction. Previous studies have demonstrated positive associations between LTL and cardiopulmonary fitness and maximal aerobic capacity (VO~2~max) among healthy adults who regularly engaged in exercise\[[@pone.0223891.ref014], [@pone.0223891.ref037]\]. Studies of LTL among COPD populations using functional exercise capacity assessments (such as 6MWT) have not been reported previously. Taken together, previous studies and our current results suggest that although LTL may be a possible molecular mechanism through which exercise capacity and mortality may be linked. The impact of sustained engagement in endurance exercise on LTL is unknown. In light of the fact that exercise capacity is both modifiable and the target of training programs such as pulmonary rehabilitation, future longitudinal studies should examine whether sustained aerobic training impacts long-term change in LTL in COPD patients.

Our analyses also support significant associations between shorter LTL and higher number of past and future AEs among several cohorts within our study. An inverse relationship between LTL and history of AE frequency in the year prior to enrollment was observed in the cohorts where quantitative retrospective data was available. The lack of association in the combined (Cohorts 1,2, & 3) analysis of dichotomized AEs (yes/no) in the year prior to enrollment is likely due in part to the reduced power of the binary phenotype. Interestingly, shorter LTL at baseline was also predictive of future AEs in Cohort 3. These results are consistent with those from a study designed to examine the efficacy of chronic macrolide therapy on AE's in COPD; a higher rate of prospectively assessed moderate-to-severe AE were associated with decreased LTL in the placebo arm of that trial \[[@pone.0223891.ref012]\]. No association between LTL and future AEs was observed in Cohorts 1 and 2 in our analyses. This may be due to 1) the longer average duration of follow up in Cohort 3, and/or 2) the broader definition of AE used in Cohort 3 (mild, moderate, and severe) relative to Cohorts 1 & 2 (moderate-to-severe AE defined as increased symptoms requiring systemic steroid and/or antibiotic use). It is not possible to infer from our cross-sectional data whether AEs reduce LTL or whether LTL simply serves as a marker of increased susceptibility towards AEs.

Despite a robust association between exercise capacity and LTL, we did not observe an association between LTL and objectively assessed PA. Factors which may have contributed to the lack of association between LTL and PA in our study include heterogeneity between cohorts with respect to study participants and PA assessment devices. Although our study was sufficiently powered to detect modest correlations (\>80% power to detect a correlation of 0.15--0.20 at an alpha level of 0.05), the existence of a threshold intensity or duration of PA required to impact LTL\[[@pone.0223891.ref038]\] may have precluded detection of an association in our studies. Alternatively, factors other than LTL, such as lung disease severity or unmeasured environmental, behavioral, and social factors, may play a larger role determining PA relative to biological or intrinsic physiological factors (e.g. cardiac output, muscle fiber oxidative capacity) among COPD patients.

In conclusion, we have demonstrated significant associations between LTL and exercise capacity and AEs. The strengths of our analyses include a biobehavioral approach to understanding PA and exercise, large number of well-characterized COPD subjects with rigorously assessed PA data, and standardized assessments of functional exercise capacity, spirometry, and comorbidities. Limitations include a predominance of males and limited representation of individuals of non-white ancestry, both of which may limit the generalizability of our findings. Cohort heterogeneity, such as differences in airflow severity, comorbidities, and baseline PA levels, as well as the use of different PA data collection devices and AE ascertainment criteria may have limited the ability to detect significant associations. However, when applicable, we have applied established statistical methods to account for these cohort differences and believe our findings support the need for additional investigations to examine the effects of PA promotion on LTL and the utility of telomeres in the prognostication of COPD-related phenotypes. Future work is needed to build on our preliminary results to understand the biobehavioral basis of the relationships between physical activity, exercise capacity, and telomere length.
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